Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of
monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent …

Uterine papillary serous carcinoma (UPSC) is a histologic variant of endometrial cancer that
accounts for only 10% of new cases of uterine cancer but is responsible for 40% of deaths …

Background Data are limited regarding the use of poly (adenosine diphosphate [ADP]–
ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed …

Background There is a high unmet need for treatment regimens that increase the chance of
long-term remission and possibly cure for women with newly diagnosed advanced ovarian …

Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy
and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer …

ABSTRACT Olaparib (Lynparza™; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with
biologic activity in ovarian cancer as well as other solid tumors. It has been tested in Phase I …

Background Late-line treatment options for patients with ovarian cancer are few, with the
proportion of patients achieving an overall response typically less than 10%, and median …

Because of nonspecific symptoms at disease presentation and inadequate screening
methods, ovarian cancer is often advanced at the time of diagnosis results in a 10-year …

Despite advances in diagnosis and therapy, an individual with ovaries carries an
approximate 1 in 108 lifetime chance to die due to ovarian cancer (OC). Primary therapy …

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian
Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) …